European Dialysis Working Group (EUDIAL)
Preliminary list of Core-members:
1) Peter Blankestijn – Chairman DoI
2) Andrew Davenport - Secretary DoI
3) Francesco Locatelli
4) Francisco Maduell DoI
5) Claudio Ronco DoI
6) James Tattersall DoI
7) Raymond Vanholder DoI
8) Christoph Wanner DoI
9) Rukshana Shroff DoI
10) Faith Kircelli DoI
Vision and mission of EUDIAL:
Improving renal outcomes by upgrading renal replacement therapies
by Bernard Canaud (1) and Peter J. Blankestijn(2) with assistance of Ingrid Ledebo(3)
(1) Nephrology, Dialysis & Intensive Care Unit, Lapeyronie University Hospital, Montpellier, France
(2) Department of Nephrology, University Medical Center, PO Box 85500, 3508 GA Utrecht, The Netherlands.
(3) Lund, Sweden
The Council of the European Renal Association-European Dialysis Transplant Association (ERA-EDTA) has officially approved the creation of a working group dedicated to the development and evaluation of innovative renal replacement therapies for chronic kidney disease patients. The acronym EUDIAL, standing for European Dialysis Working Group, has been chosen to best summarize its activity and mission. The vision and mission of this working group as formulated by the ERA-EDTA are clearly identified to improve outcomes of chronic kidney disease patients by enhancing the quality of dialysis therapies in their broader sense and facilitating collaborative research in this field.
The EUDIAL working group has been established with a core group (Board Members) to launch the activity and the group will be complemented by active members (Ordinary Members) from the European nephrology community based on their scientific interest in the field of dialysis and their wish to contribute to the activities of the working group. The membership for EUDIAL will be opened at the launch symposium during the ERA-EDTA Congress in Prague, where planned activities of the working group will also be presented. It is planned to hold two meetings per year and to report activities at the annual congress of the ERA-EDTA.
Given the increasing scientific interest in convective therapies (hemodiafiltration and hemofiltration), the working group has decided to focusing on convective renal replacement therapies as the first aim. The rationale of this first mission is supported by several facts that include an increasing interest in convective therapies translating in a rapid growth of patients treated by modern versions of these therapies and several reports suggesting an improvement in CKD patient outcomes.
In addition, the European nephrology community has been leading in this field of renal replacement therapy for more than two decades. The concept of ultrapure dialysis fluid introduced in 1987 is now accepted as a standard for all dialysis forms. The European notified bodies have certified water treatment systems and hemodialysis machines for online production of substitution fluid. The European scientific community has launched the first randomized controlled trials comparing outcomes of CKD patients treated either by hemodiafiltration/hemofiltration or conventional hemodialysis. The highest prevalence of CKD patients treated by hemodiafiltration is found in Europe and it is increasing regularly over the time.
The EUDIAL working group has identified four main topics which will be covered and assessed over the next two years:
1. Efficacy
2. Clinical effects and long-term outcomes
3. Safety and regulation
4. Economics.
A more exhaustive list of subtopics has been established and will be presented at the launching symposium during the Prague congress. In addition to these main topics, further issues will be addressed, such as establishing best practice recommendations, collecting and sharing educational material, providing literature survey with bibliographic support and creating an online renal replacement therapy data registry. It is intended that EUDIAL will coordinate its activity closely with other ERA-EDTA working groups including the uremic toxins group (EUTOX) and the cardiovascular disease group (EURECA).
In conclusion EUDIAL has the ambition of establishing new standards for renal replacement therapies and improving global care and outcomes of chronic kidney patients.
Contacts:
Prof. Peter Blankestijn (Netherlands), email: P.J.Blankestijn@umcutrecht.nl
Mrs. Marian Mijling (Prof. Blankestijn Assistant), email: eudial@era-edta.org
Planned activity EUDIAL Working Group:
 |
UPDATE IN DIALYSIS |
EUDial Dialysis Study Day
June 13, 2013
UCL Institute of Child Health, London, UK
EUDIAL symposium: 49th ERA-EDTA Congress, Paris (France) - Thursday May 24th, 2012 - 15.30-17.00 - Room 351
Recommendations based on available evidence for hemodiafiltration therapy. Report of EuDial working meeting of October 2011.
Opening/Welcome
Bernard Canaud
How to define and quantify hemodiafiltration?
James Tattersall, on behalf of Group 1
How to apply HDF in a safe way? Current safety standards, regulations and guidelines
Richard Ward, on behalf of Group 2
Available clinical evidence for HDF
Menso Nube, on behalf of Group 3 and 4
EuDial, where do we go from here?
Peter J. Blankestijn
EUDIAL symposium : XLVIII ERA-EDTA Congress, Prague (Czech Republic) - Saturday June 25th, 2011 - 14.45-16.15
Program: EuDial - ERA-EDTA Working Group on Dialysis Therapies, focusing on convective therapies.
Chairs: Vanholder R., Wanner Ch.
Canaud B, Blankestijn PJ: Future activities of EUDIAL.
Blankestijn PJ: Randomized clinical trials in Europe evaluating HDF and HD.
Ward R: International standards on fluid preparation for convective therapies.